Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 1
1976 1
1978 1
1980 5
1981 2
1982 3
1983 3
1984 4
1985 2
1986 3
1987 3
1988 7
1989 6
1990 6
1991 6
1992 7
1993 7
1994 7
1995 12
1996 13
1997 15
1998 16
1999 16
2000 19
2001 23
2002 28
2003 21
2004 32
2005 25
2006 31
2007 42
2008 51
2009 58
2010 84
2011 101
2012 102
2013 104
2014 122
2015 125
2016 117
2017 95
2018 125
2019 148
2020 149
2021 167
2022 165
2023 153
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

1,989 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean s nagaraja[Author] (1,069 results)?
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.
Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM, Venkateswaran N, Koestler M, Zhang W, Mucke L, Howell MJ, Possin KL, Kramer JH, Boxer AL, Miller BL, Nagarajan SS, Kirsch HE. Vossel K, et al. Among authors: nagarajan ss. JAMA Neurol. 2021 Nov 1;78(11):1345-1354. doi: 10.1001/jamaneurol.2021.3310. JAMA Neurol. 2021. PMID: 34570177 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: The Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) study was a phase 2a randomized double-blinded placebo-controlled crossover clinical trial of 34 adults with AD that was conducted at the University o …
DESIGN, SETTING, AND PARTICIPANTS: The Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) study was …
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau CC, Letson GD, Meyer J, Meyers PA, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M; EURAMOS collaborators. Whelan JS, et al. Among authors: nagarajan r. Ann Oncol. 2015 Feb;26(2):407-14. doi: 10.1093/annonc/mdu526. Epub 2014 Nov 24. Ann Oncol. 2015. PMID: 25421877 Free PMC article. Clinical Trial.
Sequence assembly demystified.
Nagarajan N, Pop M. Nagarajan N, et al. Nat Rev Genet. 2013 Mar;14(3):157-67. doi: 10.1038/nrg3367. Epub 2013 Jan 29. Nat Rev Genet. 2013. PMID: 23358380 Review.
Agent-Based Modeling of Microbial Communities.
Nagarajan K, Ni C, Lu T. Nagarajan K, et al. ACS Synth Biol. 2022 Nov 18;11(11):3564-3574. doi: 10.1021/acssynbio.2c00411. Epub 2022 Oct 31. ACS Synth Biol. 2022. PMID: 36315012 Free PMC article. Review.
Transcriptional and post-translational regulation of pannexins.
Boyce AKJ, Epp AL, Nagarajan A, Swayne LA. Boyce AKJ, et al. Among authors: nagarajan a. Biochim Biophys Acta Biomembr. 2018 Jan;1860(1):72-82. doi: 10.1016/j.bbamem.2017.03.004. Epub 2017 Mar 7. Biochim Biophys Acta Biomembr. 2018. PMID: 28279657 Free article. Review.
Following this, we delve into the role of post-translational modifications in the regulation of trafficking and channel properties, highlighting important work on glycosylation, phosphorylation, S-nitrosylation and proteolytic cleavage. Embedded throughout, we also highlig …
Following this, we delve into the role of post-translational modifications in the regulation of trafficking and channel properties, highligh …
Neuromyelitis optica spectrum disorder: an overview.
Ramakrishnan P, Nagarajan D. Ramakrishnan P, et al. Among authors: nagarajan d. Acta Neurobiol Exp (Wars). 2020;80(3):256-272. Acta Neurobiol Exp (Wars). 2020. PMID: 32990284 Review.
Neuromyelitis optica also known as Devic's syndrome is a rare autoimmune disorder that predominantly targets the optic nerves and the spinal cord. It is a debilitating disorder that damages a person's health. Initially it was considered as a variant of multiple scle …
Neuromyelitis optica also known as Devic's syndrome is a rare autoimmune disorder that predominantly targets the optic nerves and the …
Impaired Speaking-Induced Suppression in Alzheimer's Disease.
Kim KX, Dale CL, Ranasinghe KG, Kothare H, Beagle AJ, Lerner H, Mizuiri D, Gorno-Tempini ML, Vossel K, Nagarajan SS, Houde JF. Kim KX, et al. Among authors: nagarajan ss. eNeuro. 2023 Jun 6;10(6):ENEURO.0056-23.2023. doi: 10.1523/ENEURO.0056-23.2023. Print 2023 Jun. eNeuro. 2023. PMID: 37221089 Free PMC article.
Alzheimer's disease (AD) is a neurodegenerative disease involving cognitive impairment and abnormalities in speech and language. ...
Alzheimer's disease (AD) is a neurodegenerative disease involving cognitive impairment and abnormalities in speech and language. ...
Thioredoxin 1 promotes autophagy through transnitrosylation of Atg7 during myocardial ischemia.
Nagarajan N, Oka SI, Nah J, Wu C, Zhai P, Mukai R, Xu X, Kashyap S, Huang CY, Sung EA, Mizushima W, Titus AS, Takayama K, Mourad Y, Francisco J, Liu T, Chen T, Li H, Sadoshima J. Nagarajan N, et al. J Clin Invest. 2023 Feb 1;133(3):e162326. doi: 10.1172/JCI162326. J Clin Invest. 2023. PMID: 36480290 Free PMC article.
During ischemia, Trx1 was oxidized at Cys32-Cys35 of the oxidoreductase catalytic center and S-nitrosylated at Cys73. Unexpectedly, Atg7 Cys545-Cys548 reduced the disulfide bond in Trx1 at Cys32-Cys35 through thiol-disulfide exchange and this then allowed NO to be released …
During ischemia, Trx1 was oxidized at Cys32-Cys35 of the oxidoreductase catalytic center and S-nitrosylated at Cys73. Unexpectedly, A …
1,989 results